Antifibrinolytic Therapy for Cardiac Surgery: An Update

Anesthesiology

Volumn 123, Issue 1, 2015, Pages 214-221

  Koster, Andreas ^a   Faraoni, David ^b   Levy, Jerrold H ^c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; ECALLANTIDE; LYSINE; MDCO 2010; SERINE PROTEINASE INHIBITOR; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

BLOOD CONSERVATION; CARDIAC PATIENT; CORONARY ARTERY BYPASS GRAFT; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEART SURGERY; HIGH RISK PATIENT; HUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEIZURE; SURGICAL PATIENT; TRANSFUSION; ADVERSE EFFECTS; BLOOD LOSS, SURGICAL; CLINICAL TRIAL (TOPIC); TRENDS;

ANTIFIBRINOLYTIC AGENTS; APROTININ; BLOOD LOSS, SURGICAL; CARDIAC SURGICAL PROCEDURES; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 84937393992     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000000688     Document Type: Review

References (41)

1. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, Wijeysundera DN, Fedorko L, Yau TM: A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006; 46:327-38
2. Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, Song HK, Clough ER, Shore-Lesserson LJ, Goodnough LT, Mazer CD, Shander A, Stafford-Smith M, Waters J, Baker RA, Dickinson TA, Fitzgerald DJ, Likosky DS, Shann KG: 2011 update to the society of thoracic surgeons and the society of cardiovascular anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011; 91:944-82
3. Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation: The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354:353-65
4. Schneeweiss S, Seeger JD, Landon J, Walker AM: Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008; 358:771-83
5. Shaw AD, Stafford-Smith M, White WD, Phillips-Bute B, Swaminathan M, Milano C, Welsby IJ, Aronson S, Mathew JP, Peterson ED, Newman MF: The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008; 358:784-93
6. Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Tait G, Beattie WS: The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg 2010; 110:21-9
7. Walkden GJ, Verheyden V, Goudie R, Murphy GJ: Increased perioperative mortality following aprotinin withdrawal: A real-world analysis of blood management strategies in adult cardiac surgery. Intensive Care Med 2013; 39:1808-17
8. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussières JS, Côté D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R; BART Investigators: A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358:2319-31
9. Hébert PC, Fergusson DA, Hutton B, Mazer CD, Fremes S, Blajchman M, MacAdams C, Wells G, Robblee J, Bussières J, Teoh K; BART Investigators: Regulatory decisions pertaining to aprotinin may be putting patients at risk. CMAJ 2014; 186:1379-86
10. Meybohm P, Herrmann E, Nierhoff J, Zacharowski K: Aprotinin may increase mortality in low and intermediate risk but not in high risk cardiac surgical patients compared to tranexamic acid and-aminocaproic acid: A meta-analysis of randomised and observational trials of over 30, 000 patients. PLoS One 2013; 8:e58009
11. Hutton B, Joseph L, Fergusson D, Mazer CD, Shapiro S, Tinmouth A: Risks of harms using antifibrinolytics in cardiac surgery: Systematic review and network meta-analysis of randomised and observational studies. BMJ 2012; 345:e5798
12. Bokesch PM, Szabo G, Wojdyga R, Grocott HP, Smith PK, Mazer CD, Vetticaden S, Wheeler A, Levy JH: A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial). J Thorac Cardiovasc Surg 2012; 143:1022-9
13. Szabó G, Veres G, Radovits T, Haider H, Krieger N, Bährle S, Niklisch S, Miesel-Gröschel C, van de Locht A, Karck M: The novel synthetic serine protease inhibitor CU-2010 dosedependently reduces postoperative blood loss and improves postischemic recovery after cardiac surgery in a canine model. J Thorac Cardiovasc Surg 2010; 139:732-40
14. Englberger L, Dietrich W, Eberle B, Erdoes G, Keller D, Carrel T: A novel blood-sparing agent in cardiac surgery First in-patient experience with the synthetic serine protease inhibitor MDCO-2010: A phase II, randomized, double-blind, placebo-controlled study in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Anesth Analg 2014; 119:16-25
15. Sigaut S, Tremey B, Ouattara A, Couturier R, Taberlet C, Grassin-Delyle S, Dreyfus JF, Schlumberger S, Fischler M: Comparison of two doses of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass. Anesthesiology 2014; 120:590-600
16. Yee BE, Wissler RN, Zanghi CN, Feng C, Eaton MP: The effective concentration of tranexamic acid for inhibition of fibrinolysis in neonatal plasma in vitro. Anesth Analg 2013; 117:767-72
17. Bojko B, Vuckovic D, Mirnaghi F, Cudjoe E, Wasowicz M, Jerath A, Pawliszyn J: Therapeutic monitoring of tranexamic acid concentration: High-throughput analysis with solidphase microextraction. Ther Drug Monit 2012; 34:31-7
18. Grassin-Delyle S, Tremey B, Abe E, Fischler M, Alvarez JC, Devillier P, Urien S: Population pharmacokinetics of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass. Br J Anaesth 2013; 111:916-24
19. Grassin-Delyle S, Couturier R, Abe E, Alvarez JC, Devillier P, Urien S: A practical tranexamic acid dosing scheme based on population pharmacokinetics in children undergoing cardiac surgery. Anesthesiology 2013; 118:853-62
20. Faraoni D, Cacheux C, Van Aelbrouck C, Ickx BE, Barvais L, Levy JH: Effect of two doses of tranexamic acid on fibrinolysis evaluated by thromboelastography during cardiac surgery: A pilot, prospective, randomised, controlled study. Eur J Anaesthesiol 2014; 34:491-8
21. Faraoni D, Willems A, Melot C, De Hert S, Van der Linden P: Efficacy of tranexamic acid in paediatric cardiac surgery: A systematic review and meta-analysis. Eur J Cardiothorac Surg 2012; 42:781-6
22. Faraoni D, Rozen L, Willems A, Sanchez Torres C, Pereira LM, Demulder A, Van der Linden P: Experimental model of hyperfibrinolysis designed for rotational thromboelastometry in children with congenital heart disease. Blood Coagul Fibrinolysis 2015; 26:290-7
23. Waldow T, Szlapka M, Haferkorn M, Bürger L, Plötze K, Matschke K: Prospective clinical trial on dosage optimizing of tranexamic acid in non-emergency cardiac surgery procedures. Clin Hemorheol Microcirc 2013; 55:457-68
24. Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejia-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S: Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised, placebocontrolled trial. Lancet 2010; 376:23-32
25. Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M: High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg 2010; 110:350-3
26. Sander M, Spies CD, Martiny V, Rosenthal C, Wernecke KD, von Heymann C: Mortality associated with administration of highdose tranexamic acid and aprotinin in primary open-heart procedures: A retrospective analysis. Crit Care 2010; 14:R148
27. Koster A, Börgermann J, Zittermann A, Lueth JU, Gillis-Januszewski T, Schirmer U: Moderate dosage of tranexamic acid during cardiac surgery with cardiopulmonary bypass and convulsive seizures: Incidence and clinical outcome. Br J Anaesth 2013; 110:34-40
28. Makhija N, Sarupria A, Kumar Choudhary S, Das S, Lakshmy R, Kiran U: Comparison of-aminocaproic acid and tranexamic acid in thoracic aortic surgery: Clinical efficacy and safety. J Cardiothorac Vasc Anesth 2013; 27:1201-7
29. Martin K, Knorr J, Breuer T, Gertler R, Macguill M, Lange R, Tassani P, Wiesner G: Seizures after open heart surgery: Comparison of-aminocaproic acid and tranexamic acid. J Cardiothorac Vasc Anesth 2011; 25:20-5
30. Martin K, Breuer T, Gertler R, Hapfelmeier A, Schreiber C, Lange R, Hess J, Wiesner G: Tranexamic acid versus varepsilon-aminocaproic acid: Efficacy and safety in paediatric cardiac surgery. Eur J Cardiothorac Surg 2011; 39:892-7
31. Kratzer S, Irl H, Mattusch C, Bürge M, Kurz J, Kochs E, Eder M, Rammes G, Haseneder R: Tranexamic acid impairs-aminobutyric acid receptor type A-mediated synaptic transmission in the murine amygdala: A potential mechanism for drug-induced seizures? Anesthesiology 2014; 120:639-49
32. Lecker I, Wang DS, Romaschin AD, Peterson M, Mazer CD, Orser BA: Tranexamic acid concentrations associated with human seizures inhibit glycine receptors. J Clin Invest 2012; 122:4654-66
33. Sharma V, Katznelson R, Jerath A, Garrido-Olivares L, Carroll J, Rao V, Wasowicz M, Djaiani G: The association between tranexamic acid and convulsive seizures after cardiac surgery: A multivariate analysis in 11, 529 patients. Anaesthesia 2014; 69:124-30
34. Leminen H, Hurskainen R: Tranexamic acid for the treatment of heavy menstrual bleeding: Efficacy and safety. Int J Womens Health 2012; 4:413-21
35. Goldstone AB, Bronster DJ, Anyanwu AC, Goldstein MA, Filsoufi F, Adams DH, Chikwe J: Predictors and outcomes of seizures after cardiac surgery: A multivariable analysis of 2, 578 patients. Ann Thorac Surg 2011; 91:514-8
36. Gofton TE, Chu MW, Norton L, Fox SA, Chase L, Murkin JM, Young GB: A prospective observational study of seizures after cardiac surgery using continuous EEG monitoring. Neurocrit Care 2014; 21:220-7
37. Kikura M, Levy JH, Tanaka KA, Ramsay JG: A double-blind, placebo-controlled trial of-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery. J Am Coll Surg 2006; 202:216-22; quiz A44-5
38. Greilich PE, Jessen ME, Satyanarayana N, Whitten CW, Nuttall GA, Beckham JM, Wall MH, Butterworth JF: The effect of-aminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: A randomized, double-blind, placebo-controlled, noninferiority trial. Anesth Analg 2009; 109:15-24
39. Sarupria A, Makhija N, Lakshmy R, Kiran U: Comparison of different doses of-aminocaproic acid in children for tetralogy of Fallot surgery: Clinical efficacy and safety. J Cardiothorac Vasc Anesth 2013; 27:23-9
40. Martin K, Gertler R, MacGuill M, Mayr NP, Hapfelmeier A, Hörer J, Vogt M, Tassani P, Wiesner G: Replacement of aprotinin by-aminocaproic acid in infants undergoing cardiac surgery: Consequences for blood loss and outcome. Br J Anaesth 2013; 110:615-21
41. Scott JP, Costigan DJ, Hoffman GM, Simpson PM, Dasgupta M, Punzalan R, Berens RJ, Tweddell JS, Stuth EA: Increased recombinant activated factor VII use and need for surgical reexploration following a switch from aprotinin to-aminocaproic acid in infant cardiac surgery. J Clin Anesth 2014; 26:204-11